ASX ANNOUNCEMENT

Results of Annual General Meeting

Wednesday, 18 November 2026

Ceryvyn Therapeutics Limited (ASX:CYV) ("Ceryvyn" or the "Company") advises that in accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), the results of the resolutions put to shareholders at today's Annual General Meetings are included in the attached document. All resolutions were carried by the requisite majority.

This announcement has been authorised for release by the Board of Directors.

About Ceryvyn Therapeutics (ASX: CYV)

Ceryvyn Therapeutics Ltd (ASX: CYV) is a clinical-stage biopharmaceutical company developing innovative therapies by translating advances in human biology into transformative medicines for patients with serious diseases. The Company seeks to identify biological mechanisms that drive disease and develop targeted therapies capable of addressing significant unmet medical need.

Ceryvyn's current focus is lymphangioleiomyomatosis (LAM) - a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. Despite currently available therapies, there remains no cure and significant unmet medical need.

The Company's lead development program, CYV-101, is a first-in-class fusion protein designed to selectively bind and neutralise VEGF-C and VEGF-D, key signalling proteins involved in pathological lymphangiogenesis. By targeting a fundamental biological pathway believed to

drive disease progression, CYV-101 has the potential to offer a differentiated therapeutic approach for patients with LAM.

Ceryvyn is committed to building a biotechnology company grounded in scientific excellence, rigorous clinical development and a relentless focus on improving the lives of patients while creating sustainable long-term value for shareholders.

To learn more, visit our website as www.ceryvyn.com and follow us on LinkedIn.

Contact

investor@ceryvyn.com
media@ceryvyn.com

Ceryvyn Therapeutics Limited
Annual General Meeting
Wednesday, 18 November 2026
Results of Meeting

Computershare

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adopt Remuneration Report	Ordinary	274,418,743 93.15%	19,837,595 6.73%	358,370 0.12%	3,401,500	274,791,789 93.27%	19,837,595 6.73%	3,401,500	Carried
2 Re-election of Mr Lawrence Gozlan as a Director	Ordinary	283,939,917 94.67%	15,639,389 5.21%	350,370 0.12%	86,532	284,304,963 94.79%	15,639,389 5.21%	86,532	Carried
3 Appointment of auditor	Ordinary	284,911,959 94.99%	14,661,234 4.89%	350,095 0.12%	92,920	285,276,730 95.11%	14,661,234 4.89%	92,920	Carried
4 Approval of Employee Awards Plan	Ordinary	274,029,266 92.29%	22,523,017 7.59%	358,095 0.12%	1,105,830	274,402,037 92.41%	22,523,017 7.59%	1,105,830	Carried
5 Issue of Options to Dr Jeremy Levin (and/or his nominee(s)) under the Employee Awards Plan	Ordinary	274,170,447 92.34%	22,381,736 7.54%	358,733 0.12%	1,105,292	274,543,856 92.46%	22,381,736 7.54%	1,105,292	Carried
6 Approval of potential benefits to Dr Jeremy Levin (and/or his nominee(s)) in relation to Options	Ordinary	273,867,539 92.26%	22,642,411 7.63%	347,082 0.11%	1,159,176	274,229,297 92.37%	22,642,411 7.63%	1,159,176	Carried
7 Issue of Options to Ms Kathy Connell (and/or her nominee (s)) under the Employee Awards Plan	Ordinary	272,701,797 91.85%	23,874,066 8.04%	347,082 0.11%	1,093,263	273,063,555 91.96%	23,874,066 8.04%	1,093,263	Carried
8 Approval of potential benefits to Ms Kathy Connell (and/or her nominee(s)) in relation to Options	Ordinary	272,696,855 91.84%	23,871,066 8.04%	355,024 0.12%	1,093,263	273,066,555 91.96%	23,871,066 8.04%	1,093,263	Carried
9 Issue of Options to Mr Lawrence Gozlan (and/or his nominee(s)) under the Employee Awards Plan	Ordinary	272,690,297 91.85%	23,885,566 8.04%	347,082 0.11%	1,093,263	273,052,055 91.96%	23,885,566 8.04%	1,093,263	Carried
10 Approval of potential benefits to Mr Lawrence Gozlan (and/ or his nominee(s)) in relation to Options	Ordinary	272,690,297 91.85%	23,885,566 8.04%	347,082 0.11%	1,093,263	273,052,055 91.96%	23,885,566 8.04%	1,093,263	Carried
11 Amendment of the Consitition	Special	284,356,924 94.94%	14,795,220 4.94%	358,095 0.12%	505,969	284,729,695 95.06%	14,795,220 4.94%	505,969	Carried
12 Approval of additional 10% placement capacity	Special	276,149,275 92.06%	23,468,335 7.82%	358,095 0.12%	40,503	276,522,046 92.18%	23,468,335 7.82%	40,503	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.